Aquestive Therapeutics, Inc. v. BioDelivery Sciences International, Inc. > Documents

Date Field	Doc. No.	Description (Pages)
Mar 8, 2023	126	STIPULATION of Dismissal (JOINT) by Aquestive Therapeutics, Inc. (Evans, E.) (Entered: 03/08/2023) (2)
Jan 24, 2023	124	ORDER regarding Sanctions - Signed by US Magistrate Judge Robert T. Numbers, II on 1/24/2023. (Sellers, N.) (Entered: 01/24/2023) (6)
Jan 24, 2023	125	ORDER regarding deadlines for determination of fees and costs - Signed by US Magistrate Judge Robert T. Numbers, II on 1/24/2023. (Sellers, N.) (Entered: 01/24/2023) (5)
Dec 16, 2022	123	OFFICIAL TRANSCRIPT of Proceedings held on 11/17/2022, Show Cause Hearing, before Judge Robert T. Number, II. Court Transcriber: eScribers, Telephone number 973-406-2250, www.escribers.net. Transcript may be viewed at the court public terminal or purchased through the Court Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Please review Attorney obligations regarding the redaction of electronic transcripts of court proceedings available on the court's website Redaction Request due 1/9/2023. Redacted Transcript Deadline set for 1/19/2023. Release of Transcript Restriction set for 3/19/2023. (Foell, S.) (Entered: 12/16/2022) (0)
Nov 17, 2022	122	Minute Entry for proceedings held before Magistrate Judge Robert T. Numbers, II in Raleigh - Show Cause Hearing held on 11/17/2022. Parties present. Parties speak to their respective positions. The Court takes this matter under advisement and will issue a written order. (Court Reporter - FTR) (Brewer, C) (Additional attachment(s) added on 11/29/2022: # 1 Amended Minutes) (Brewer, C). (Entered: 11/17/2022) (0)
Nov 16, 2022	118	RESPONSE regarding 117 Response,,, filed by Aquestive Therapeutics, Inc.. (Evans, E.) (Entered: 11/16/2022) (10)
Nov 16, 2022	119	Declaration regarding 118 Response (Reply) to McCarter & English, LLP's Response to the Court's Order to Show Cause by Aquestive Therapeutics, Inc. (Attachments: # 1 Exhibit A - BDSI Second Amended Responses to Plaintiff's First Set of Interrogatories (Redacted)) (Evans, E.) (Entered: 11/16/2022) (Main Document) (1)
Nov 16, 2022	120	PROPOSED SEALED Exhibit (Selected Participants Only)by Aquestive Therapeutics, Inc. (available to: Plaintiff Aquestive Therapeutics, Inc., Defendant BioDelivery Sciences International, Inc., Interested Party McCarter & English, LLP) regarding 119 Declaration,. (Evans, E.) (Entered: 11/16/2022) (0)
Nov 16, 2022	121	Notice filed by Aquestive Therapeutics, Inc. regarding 120 PROPOSED SEALED Exhibit, (Provisional Filing Under Seal). (Evans, E.) (Entered: 11/16/2022) (2)
Nov 16, 2022	119	Declaration regarding 118 Response (Reply) to McCarter & English, LLP's Response to the Court's Order to Show Cause by Aquestive Therapeutics, Inc. (Attachments: # 1 Exhibit A - BDSI Second Amended Responses to Plaintiff's First Set of Interrogatories (Redacted)) (Evans, E.) (Entered: 11/16/2022) (Exhibit A - BDSI Second Amended Responses to Plaintiff's First Set of Inter) (18)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Main Document) (8)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Declaration of Kia L. Freeman) (2)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of rec) (2)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of rec) (2)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No.) (3)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (N) (13)
Nov 14, 2022	117	RESPONSE to Order regarding 113 Set Deadlines/Hearings - McCarter & English, LLP's Response to the Court's Order to Show Cause Dated October 21, 2022 113 filed by McCarter & English, LLP. (Attachments: # 1 Declaration of Kia L. Freeman, # 2 Exhibit A - letter dated September 10, 2022 from Thomas Foley to counsel of record (No. 5:19-cv-00505), # 3 Exhibit B - letter dated September 16, 2022 from Thomas Foley to counsel of record (No. 5:15-cv-00350), # 4 Exhibit C - email dated June 8, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350), # 5 Exhibit D - letter dated June 22, 2022 from Kia Freeman to counsel of record (No. 5:15-cv-00350 and No. 5:19-cv-00505) REDACTED, # 6 Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake Holdreith and Jamie Lucia) (Cahill, Daniel) (Entered: 11/14/2022) (Exhibit E - email chain dated August 30, 2022 to September 2, 2022 between Jake) (5)
Nov 4, 2022	116	Notice of Appearance (2) Docket Text: Notice of Appearance filed by Daniel G. Cahill on behalf of McCarter & English, LLP. (Cahill, Daniel)
Nov 3, 2022	N/A	Notice of Filing of Official Transcript (0) Docket Text: NOTICE of Filing of Official Transcript [115] Transcript. The parties have seven calendar days from the filing of the transcript to file a Notice of Intent to Request Redaction. The parties must also serve a copy on the court reporter or transcriber. After filing the Notice of Intent to Request Redaction, a party must submit to the court reporter or transcriber, within 21 calendar days of the filing of the transcript, a written statement indicating where the personal data identifiers to be redacted appear in the transcript. (Foell, S.)
Oct 25, 2022	N/A	Notice of Filing of Official Transcript (0) Docket Text: NOTICE of Filing of Official Transcript [114] Transcript. The parties have seven calendar days from the filing of the transcript to file a Notice of Intent to Request Redaction. The parties must also serve a copy on the court reporter or transcriber. After filing the Notice of Intent to Request Redaction, a party must submit to the court reporter or transcriber, within 21 calendar days of the filing of the transcript, a written statement indicating where the personal data identifiers to be redacted appear in the transcript. (Foell, S.)
Oct 21, 2022	113	Set Deadlines/Hearings (2) Docket Text: Order Setting Hearings - Show Cause Hearing set for 11/17/2022 at 01:30 PM in Raleigh - Courtroom TBA before US Magistrate Judge Robert T. Numbers II. Signed by US Magistrate Judge Robert T. Numbers, II on 10/21/2022. (Sellers, N.)
Oct 17, 2022	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [111] MOTION to Withdraw as Attorney ATTORNEYS FROM MCCARTER & ENGLISH, LLP, K. FREEMAN, W. PROCTOR, & T. FOLEY. (Sellers, N.)
Oct 17, 2022	112	Order on Motion to Withdraw as Attorney (1) Docket Text: ORDER granting [111] Motion to Withdraw as Attorney. Attorney Wyley S. Proctor; Thomas F. Foley and Kia L. Freeman terminated. Signed by District Judge James C. Dever III on 10/17/2022. (Sellers, N.)
Oct 14, 2022	111	Motion to Withdraw as Attorney (Main Document) (4) Docket Text: MOTION to Withdraw as Attorney ATTORNEYS FROM MCCARTER & ENGLISH, LLP, K. FREEMAN, W. PROCTOR, & T. FOLEY filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Freeman, Kia)
Oct 14, 2022	111	Motion to Withdraw as Attorney (Text of Proposed Order) (1) Docket Text: MOTION to Withdraw as Attorney ATTORNEYS FROM MCCARTER & ENGLISH, LLP, K. FREEMAN, W. PROCTOR, & T. FOLEY filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Freeman, Kia)
Oct 5, 2022	N/A	Notice to Counsel (0) Docket Text: Notice to Counsel regarding: [110] Notice of Change of Address. You will have to update your address information through Pacer for your information to appear correct on our docket. (Sellers, N.)
Oct 4, 2022	N/A	Order on Motion for Leave to File (0) Docket Text: TEXT ORDER: The court denies as moot Aquestive Therapeutics motion for leave to file a reply (D.E. 87). Signed by US Magistrate Judge Robert T. Numbers, II on 10/4/2022. (Sellers, N.)
Oct 4, 2022	110	Notice of Change of Address (2) Docket Text: Notice of Change of Address filed by Jamie Lucia filed by on behalf of Aquestive Therapeutics, Inc.. (Lucia, Jamie)
Oct 3, 2022	109	Order on Motion to Compel (2) Docket Text: ORDER granting [78], [105] Motion to Compel. Counsel should read the order in its entirety for critical deadlines and information. Signed by US Magistrate Judge Robert T. Numbers, II on 10/3/2022. (Sellers, N.)
Sep 22, 2022	107	Response in Opposition to Motion (Main Document) (10) Docket Text: RESPONSE in Opposition regarding [105] Corrected MOTION to Compel Discovery filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit Freeman Declaration) (Siddoway, Peter)
Sep 22, 2022	107	Response in Opposition to Motion (Exhibit Freeman Declaration) (4) Docket Text: RESPONSE in Opposition regarding [105] Corrected MOTION to Compel Discovery filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit Freeman Declaration) (Siddoway, Peter)
Sep 19, 2022	105	Motion to Compel (Main Document) (2) Docket Text: Corrected MOTION to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Sep 19, 2022	105	Motion to Compel (Text of Proposed Order) (1) Docket Text: Corrected MOTION to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Sep 19, 2022	106	Motion for Leave to File (Main Document) (2) Docket Text: Corrected MOTION for Leave to File Reply In Support of Motion to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Reply, # (2) Exhibit - Declaration of J. Lucia In Support, # (3) Text of Proposed Order) (Evans, E.)
Sep 19, 2022	106	Motion for Leave to File (Exhibit A - Proposed Reply) (6) Docket Text: Corrected MOTION for Leave to File Reply In Support of Motion to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Reply, # (2) Exhibit - Declaration of J. Lucia In Support, # (3) Text of Proposed Order) (Evans, E.)
Sep 19, 2022	106	Motion for Leave to File (Exhibit - Declaration of J. Lucia In Support) (10) Docket Text: Corrected MOTION for Leave to File Reply In Support of Motion to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Reply, # (2) Exhibit - Declaration of J. Lucia In Support, # (3) Text of Proposed Order) (Evans, E.)
Sep 19, 2022	106	Motion for Leave to File (Text of Proposed Order) (1) Docket Text: Corrected MOTION for Leave to File Reply In Support of Motion to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Reply, # (2) Exhibit - Declaration of J. Lucia In Support, # (3) Text of Proposed Order) (Evans, E.)
Sep 15, 2022	104	Order (1) Docket Text: ORDER - On July 28, 2022, Aquestive Therapeutics, Inc. ("Aquestive") filed a consent motion to compel in this case and in case No. 5:15-CV-350-D. See [D.E.78]. On August 12,2022, Aquestive filed a motion for leave to file a reply in support of its motion to compel discovery in this case and in case No. 5:19-CV-505-D. See [D.E. 87]. Case numbers 5:15-CV-350-D and 5:19-CV-505-D arenot consolidated cases. Aquestive shall refile its motions in the appropriate case not later than September 19, 2022. Signed by District Judge James C. Dever III on 9/15/2022. (Sellers, N.)
Sep 13, 2022	N/A	Set/Reset Hearings (0) Docket Text: **** Set Hearing: Discovery Status Hearing set for 9/27/2022 at 03:30 PM via videoconference before Magistrate Judge Robert T. Numbers II. Clerk to provide the parties with the necessary information to join the videoconference. (Brewer, C)
Sep 12, 2022	101	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by John W. Toth on behalf of Aquestive Therapeutics, Inc.. (Toth, John)
Sep 12, 2022	102	Order on Motion to Withdraw as Attorney (1) Docket Text: ORDER granting [99] Motion to Withdraw as Attorney. Attorney Anna M. Targowska terminated. Signed by District Judge James C. Dever III on 9/12/2022. (Sellers, N.)
Sep 9, 2022	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [99] MOTION to Withdraw as Attorney. (Sellers, N.)
Sep 9, 2022	100	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Jake M. Holdreith on behalf of BioDelivery Sciences International, Inc.. (Holdreith, Jake)
Sep 8, 2022	99	Motion to Withdraw as Attorney (Main Document) (2) Docket Text: MOTION to Withdraw as Attorney filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Targowska, Anna)
Sep 8, 2022	99	Motion to Withdraw as Attorney (Text of Proposed Order) (1) Docket Text: MOTION to Withdraw as Attorney filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Targowska, Anna)
Sep 2, 2022	N/A	Order Setting Hearing on Motion (0) Docket Text: TEXT ORDER Setting Hearing on Motion [78] MOTION to Compel Discovery : Motion Hearing set for 9/13/2022 at 01:30 PM in Raleigh - 5th Floor Courtroom before Magistrate Judge Robert T. Numbers II. Counsel may appear at the hearing via video conference (or telephonically if video conference capabilities are unavailable). Counsel shall contact the undersigneds case manager no later than one week before the hearing to make the necessary arrangements. Entered by Magistrate Judge Robert T. Numbers, II on 9/2/2022. (Brewer, C)
Sep 2, 2022	96	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Oren Langer on behalf of BioDelivery Sciences International, Inc.. (Langer, Oren)
Sep 2, 2022	97	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Emily Tremblay on behalf of BioDelivery Sciences International, Inc.. (Tremblay, Emily)
Sep 2, 2022	98	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Christopher A Pinahs on behalf of BioDelivery Sciences International, Inc.. (Pinahs, Christopher)
Aug 31, 2022	93	Order on Motion to Seal Document (3) Docket Text: ORDER granting [85] MOTION to Seal [79] PROPOSED SEALED Memorandum in Support. Signed by District Judge James C. Dever, III on 8/30/2022. (Stouch, L.)
Aug 31, 2022	94	Order Referring Motion (1) Docket Text: ORDER REFERRING MOTION: [87] MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc. Motion referred to Robert T. Numbers, II. Signed by District Judge James C. Dever, III on 8/30/2022. (Stouch, L.)
Aug 31, 2022	95	Order on Motion to Strike (1) Docket Text: ORDER denying [67] Motion to Strike Portions of Aquestive's Infringement Contentions. Signed by District Judge James C. Dever, III on 8/30/2022. (Stouch, L.)
Aug 17, 2022	91	Status Report (3) Docket Text: STATUS REPORT (Joint) by Aquestive Therapeutics, Inc. (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Main Document) (4) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Exhibit A - [Proposed] Reply in Support of Motion to Compel) (7) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed]) (3) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Free) (3) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Luci) (4) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	87	Motion for Leave to File (Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (2) Docket Text: MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - [Proposed] Reply in Support of Motion to Compel, # (2) Exhibit Declaration of Jamie L. Lucia in Support of Aquestive's [Proposed] Reply, # (3) Exhibit EE - Exhibit to Declaration of Jamie L. Lucia - 2022.07.28 Ltr from Freeman to Lucia, # (4) Exhibit FF - Exhibit to Declaration of Jamie L. Lucia - 2022.08.05 Ltr from Lucia to Freeman, # (5) Text of Proposed Order [Proposed] Order re Motion for Leave to File Reply) (Evans, E.)
Aug 12, 2022	88	Memorandum in Support (4) Docket Text: Memorandum in Support regarding [87] MOTION for Leave to File a Reply in Support of Motion to Compel filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Aug 12, 2022	90	Notice - other (4) Docket Text: Notice filed by Aquestive Therapeutics, Inc. regarding [89] PROPOSED SEALED Reply,, Notice of Provisional Filing Under Seal. (Evans, E.)
Aug 11, 2022	84	Response in Opposition to Motion (Main Document) (10) Docket Text: RESPONSE in Opposition regarding [78] MOTION to Compel Discovery filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit Freeman Declaration) (Siddoway, Peter)
Aug 11, 2022	84	Response in Opposition to Motion (Exhibit Freeman Declaration) (4) Docket Text: RESPONSE in Opposition regarding [78] MOTION to Compel Discovery filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit Freeman Declaration) (Siddoway, Peter)
Aug 11, 2022	85	Motion to Seal Document (Main Document) (5) Docket Text: MOTION to Seal [79] PROPOSED SEALED Memorandum in Support filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter) Modified on 8/12/2022 - changed docket entry relationship. (Sellers, N.)
Aug 11, 2022	85	Motion to Seal Document (Text of Proposed Order) (3) Docket Text: MOTION to Seal [79] PROPOSED SEALED Memorandum in Support filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter) Modified on 8/12/2022 - changed docket entry relationship. (Sellers, N.)
Aug 11, 2022	86	Memorandum in Support (Main Document) (7) Docket Text: Memorandum in Support regarding [85] MOTION to Seal [79] PROPOSED SEALED Memorandum in Support filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit X (redacted)) (Siddoway, Peter) Modified on 8/12/2022 - clarified docket text. (Sellers, N.)
Aug 11, 2022	86	Memorandum in Support (Exhibit X (redacted)) (6) Docket Text: Memorandum in Support regarding [85] MOTION to Seal [79] PROPOSED SEALED Memorandum in Support filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit X (redacted)) (Siddoway, Peter) Modified on 8/12/2022 - clarified docket text. (Sellers, N.)
Aug 8, 2022	83	Order Referring Motion (1) Docket Text: ORDER REFERRING MOTION: [78] MOTION to Compel Discovery filed by Aquestive Therapeutics, Inc. Motion referred to US Magistrate Judge Robert T. Numbers, II. Signed by District Judge James C. Dever III on 8/8/2022. (Sellers, N.)
Jul 28, 2022	78	Motion to Compel (Main Document) (3) Docket Text: MOTION to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Jul 28, 2022	78	Motion to Compel (Text of Proposed Order) (2) Docket Text: MOTION to Compel Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Jul 28, 2022	80	Declaration (6) Docket Text: Declaration regarding [78] MOTION to Compel Discovery (In Support of) by Aquestive Therapeutics, Inc. (Evans, E.)
Jul 28, 2022	81	Redacted Document (Main Document) (16) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Index of Exhibits) (1) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit A - U.S. Patent 8,765,167) (30) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit B - Aquestive's First Set of RFP (5050) (13) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit C - Aquestive's First Set of RFP (350)) (14) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit D - Aquestive's Second Set of RFP (5050) (20) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit E - Plaintiff's Second Set of RFP (350)) (21) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit F - BDSI's Responses to First Set of RFP (505)) (18) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit G - BDSI's Responses to First Set of RFP (350)) (20) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit H - BDSI's Responses to Second Set of RFP (505)) (30) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit I - BDSI's Responses to Second Set of RFP (350)) (30) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit J - 2021.10.25 Targowska Letter) (4) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit K - 2021.11.05 Freeman Letter) (3) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit L - 2021.11.08 BDSI Production Letter) (3) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit M - 2021.11.11 Targowska Letter) (2) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit N - 2022.01.23 Foley Email) (4) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit O - 2022.02.02 Gelwicks Letter) (6) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit P - 2022.02.16 Freeman Email) (3) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit Q - 2022.02.19 Gelwicks Email) (5) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit R - 2021 to 2022 Email Conversation) (16) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit S - 2022.03.02 Foley Email) (8) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit T - February 2022 to March 2022 Email Conversation) (12) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit U - 2022.01.26 Aquestive Production Email) (2) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit V - 2022.05.31 Aquestive Production Letter) (2) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit W - 2022.07.05 Aquestive Production Letter) (2) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit Y - 2022.06.27 Lucia Letter) (4) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit Z - 2022.07.06 Freeman Letter) (3) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505)) (28) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505)) (30) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	81	Redacted Document (Exhibit DD - 2022.02.14 Evans Email) (10) Docket Text: REDACTION to [79] PROPOSED SEALED Memorandum in Support, by Aquestive Therapeutics, Inc. (Attachments: # (1) Index of Exhibits, # (2) Exhibit A - U.S. Patent 8,765,167, # (3) Exhibit B - Aquestive's First Set of RFP (5050, # (4) Exhibit C - Aquestive's First Set of RFP (350), # (5) Exhibit D - Aquestive's Second Set of RFP (5050, # (6) Exhibit E - Plaintiff's Second Set of RFP (350), # (7) Exhibit F - BDSI's Responses to First Set of RFP (505), # (8) Exhibit G - BDSI's Responses to First Set of RFP (350), # (9) Exhibit H - BDSI's Responses to Second Set of RFP (505), # (10) Exhibit I - BDSI's Responses to Second Set of RFP (350), # (11) Exhibit J - 2021.10.25 Targowska Letter, # (12) Exhibit K - 2021.11.05 Freeman Letter, # (13) Exhibit L - 2021.11.08 BDSI Production Letter, # (14) Exhibit M - 2021.11.11 Targowska Letter, # (15) Exhibit N - 2022.01.23 Foley Email, # (16) Exhibit O - 2022.02.02 Gelwicks Letter, # (17) Exhibit P - 2022.02.16 Freeman Email, # (18) Exhibit Q - 2022.02.19 Gelwicks Email, # (19) Exhibit R - 2021 to 2022 Email Conversation, # (20) Exhibit S - 2022.03.02 Foley Email, # (21) Exhibit T - February 2022 to March 2022 Email Conversation, # (22) Exhibit U - 2022.01.26 Aquestive Production Email, # (23) Exhibit V - 2022.05.31 Aquestive Production Letter, # (24) Exhibit W - 2022.07.05 Aquestive Production Letter, # (25) SEALED Exhibit X - 2022.06.09 Freeman Email (Sealed pursuant to [93] Order), # (26) Exhibit Y - 2022.06.27 Lucia Letter, # (27) Exhibit Z - 2022.07.06 Freeman Letter, # (28) Exhibit BB - 2022.01.22 Aquestive 3rd Party Subpoena Notice (505), # (29) Exhibit CC - 2022.02.07 ARx Objections to Subpoenas (505), # (30) Exhibit DD - 2022.02.14 Evans Email) (Evans, E.) Modified on 8/31/2022 (Stouch, L.).
Jul 28, 2022	82	Notice - other (3) Docket Text: Notice of Provisional Filing Under Seal filed by Aquestive Therapeutics, Inc. regarding [79] PROPOSED SEALED Memorandum in Support. (Evans, E.)
May 4, 2022	77	Financial Disclosure Statement (2) Docket Text: Financial Disclosure Statement by BioDelivery Sciences International, Inc. identifying Corporate Parent Collegium Pharmaceuticals, Inc. for BioDelivery Sciences International, Inc.. (Siddoway, Peter)
Dec 16, 2021	75	Responsive Claim Construction Brief (Main Document) (30) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	75	Responsive Claim Construction Brief (Exhibit J - Pather Deposition Excerpts) (13) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	75	Responsive Claim Construction Brief (Exhibit K - Mathiowitz Deposition Excerpts) (14) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	75	Responsive Claim Construction Brief (Exhibit L - U.S. Patent 8,603,514 B2) (30) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	75	Responsive Claim Construction Brief (Exhibit M - U.S. Patent 8,900,497 B2) (30) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	75	Responsive Claim Construction Brief (Exhibit N - U.S. Patent 9,931,305 B2) (30) Docket Text: Responsive Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit J - Pather Deposition Excerpts, # (2) Exhibit K - Mathiowitz Deposition Excerpts, # (3) Exhibit L - U.S. Patent 8,603,514 B2, # (4) Exhibit M - U.S. Patent 8,900,497 B2, # (5) Exhibit N - U.S. Patent 9,931,305 B2) (Evans, E.)
Dec 16, 2021	76	Responsive Claim Construction Brief (Main Document) (17) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 23 - Petition IPR2015-00165) (6) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 24 - Decision on Appeal 10_074272) (4) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 25 - Myers Decl) (8) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 26 - PO Reply 90_012097) (5) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 27 - Summary of Interview 90_012097) (6) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 28 - Decision on Appeal 95-001753) (13) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Dec 16, 2021	76	Responsive Claim Construction Brief (Exhibit 29 - Cohen Decl) (22) Docket Text: Responsive Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 23 - Petition IPR2015-00165, # (2) Exhibit 24 - Decision on Appeal 10_074272, # (3) Exhibit 25 - Myers Decl, # (4) Exhibit 26 - PO Reply 90_012097, # (5) Exhibit 27 - Summary of Interview 90_012097, # (6) Exhibit 28 - Decision on Appeal 95-001753, # (7) Exhibit 29 - Cohen Decl) (Siddoway, Peter)
Nov 18, 2021	73	Opening Claim Construction Brief (Main Document) (30) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit A - Patent 8,765,167) (30) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit B - Pather Declaration) (30) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit C - Pather Deposition) (23) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit D - BDSI Preliminary Invalidity Contentions) (30) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit E - Patent 5,881,476) (30) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit F - Rounds Declaration) (20) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit G - Patent 5,393,528) (12) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit H - 2010 Response to Office Action) (21) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	73	Opening Claim Construction Brief (Exhibit I - Patent 7,425,292) (28) Docket Text: Opening Claim Construction Brief by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Patent 8,765,167, # (2) Exhibit B - Pather Declaration, # (3) Exhibit C - Pather Deposition, # (4) Exhibit D - BDSI Preliminary Invalidity Contentions, # (5) Exhibit E - Patent 5,881,476, # (6) Exhibit F - Rounds Declaration, # (7) Exhibit G - Patent 5,393,528, # (8) Exhibit H - 2010 Response to Office Action, # (9) Exhibit I - Patent 7,425,292) (Evans, E.)
Nov 18, 2021	74	Opening Claim Construction Brief (Main Document) (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit (Attachment A) Comparison of citations to '514 patent to '167) (4) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 1 - Vivelle film dosage prescribing information) (21) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 2 - "Transdermal patches") (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 3 - '167 Patent) (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 4 - '292 Patent) (28) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 5 - Mathiowitz Decl.) (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 6 - PO Response) (4) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 7 - Pather Transcript) (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 8 - Mathiowitz Transcript) (5) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 9 - Response) (17) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 10 - Response) (27) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 11 - Meyers Transcript) (11) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 12 - Decision) (30) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 13 - Response) (17) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 14 - Office Action) (6) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 15 - Application No. 11/517,982) (2) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 16 - Response) (21) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 17 - Office Action) (19) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 18 - '528 Patent) (12) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 19 - Response) (16) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 20 - Office Action) (15) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 21 - Rounds Decl.) (21) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 18, 2021	74	Opening Claim Construction Brief (Exhibit 22 - Appeal Brief) (7) Docket Text: Opening Claim Construction Brief by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit (Attachment A) Comparison of citations to '514 patent to '167 patent disclosure, # (2) Exhibit 1 - Vivelle film dosage prescribing information, # (3) Exhibit 2 - "Transdermal patches", # (4) Exhibit 3 - '167 Patent, # (5) Exhibit 4 - '292 Patent, # (6) Exhibit 5 - Mathiowitz Decl., # (7) Exhibit 6 - PO Response, # (8) Exhibit 7 - Pather Transcript, # (9) Exhibit 8 - Mathiowitz Transcript, # (10) Exhibit 9 - Response, # (11) Exhibit 10 - Response, # (12) Exhibit 11 - Meyers Transcript, # (13) Exhibit 12 - Decision, # (14) Exhibit 13 - Response, # (15) Exhibit 14 - Office Action, # (16) Exhibit 15 - Application No. 11/517,982, # (17) Exhibit 16 - Response, # (18) Exhibit 17 - Office Action, # (19) Exhibit 18 - '528 Patent, # (20) Exhibit 19 - Response, # (21) Exhibit 20 - Office Action, # (22) Exhibit 21 - Rounds Decl., # (23) Exhibit 22 - Appeal Brief) (Siddoway, Peter)
Nov 2, 2021	72	Notice of Special Appearance (2) Docket Text: Notice of Special Appearance for non-district by Daniel F. Gelwicks on behalf of Aquestive Therapeutics, Inc.. (Gelwicks, Daniel)
Nov 1, 2021	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions. (Sellers, N.)
Oct 18, 2021	71	Reply to Response to Motion (Main Document) (13) Docket Text: REPLY to Response to Motion regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit B - BDSI's LPR 304.2 Disclosure) (Siddoway, Peter)
Oct 18, 2021	71	Reply to Response to Motion (Exhibit B - BDSI's LPR 304.2 Disclosure) (9) Docket Text: REPLY to Response to Motion regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit B - BDSI's LPR 304.2 Disclosure) (Siddoway, Peter)
Oct 4, 2021	69	Joint Claim Construction Statement (Main Document) (28) Docket Text: Joint Claim Construction Statement by Aquestive Therapeutics, Inc.. (Attachments: # (1) Attachment A - Parties' Proposed Constructions, # (2) Attachment B - Plaintiff's Proposed Constructions, # (3) Attachment C - Defendant's Proposed Constructions, # (4) Attachment D - Declaration of E. Mathiowitz) (Evans, E.)
Oct 4, 2021	69	Joint Claim Construction Statement (Attachment A - Parties' Proposed Constructions) (5) Docket Text: Joint Claim Construction Statement by Aquestive Therapeutics, Inc.. (Attachments: # (1) Attachment A - Parties' Proposed Constructions, # (2) Attachment B - Plaintiff's Proposed Constructions, # (3) Attachment C - Defendant's Proposed Constructions, # (4) Attachment D - Declaration of E. Mathiowitz) (Evans, E.)
Oct 4, 2021	69	Joint Claim Construction Statement (Attachment B - Plaintiff's Proposed Constructions) (28) Docket Text: Joint Claim Construction Statement by Aquestive Therapeutics, Inc.. (Attachments: # (1) Attachment A - Parties' Proposed Constructions, # (2) Attachment B - Plaintiff's Proposed Constructions, # (3) Attachment C - Defendant's Proposed Constructions, # (4) Attachment D - Declaration of E. Mathiowitz) (Evans, E.)
Oct 4, 2021	69	Joint Claim Construction Statement (Attachment C - Defendant's Proposed Constructions) (11) Docket Text: Joint Claim Construction Statement by Aquestive Therapeutics, Inc.. (Attachments: # (1) Attachment A - Parties' Proposed Constructions, # (2) Attachment B - Plaintiff's Proposed Constructions, # (3) Attachment C - Defendant's Proposed Constructions, # (4) Attachment D - Declaration of E. Mathiowitz) (Evans, E.)
Oct 4, 2021	69	Joint Claim Construction Statement (Attachment D - Declaration of E. Mathiowitz) (30) Docket Text: Joint Claim Construction Statement by Aquestive Therapeutics, Inc.. (Attachments: # (1) Attachment A - Parties' Proposed Constructions, # (2) Attachment B - Plaintiff's Proposed Constructions, # (3) Attachment C - Defendant's Proposed Constructions, # (4) Attachment D - Declaration of E. Mathiowitz) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Main Document) (23) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit A - Plaintiff's Initial Infringement Contentions) (9) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions) (30) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit C - Defendant's Preliminary Invalidity Contentions) (30) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit D - Defendant's Claim Terms for Construction) (4) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit E - Defendant's Preliminary Constructions) (9) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Oct 4, 2021	70	Response in Opposition to Motion (Exhibit F - Plaintiff's Preliminary Infringement Contentions) (9) Docket Text: RESPONSE in Opposition regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Plaintiff's Initial Infringement Contentions, # (2) Exhibit B - Exhibit to Plaintiff's Initial Infringement Contentions, # (3) Exhibit C - Defendant's Preliminary Invalidity Contentions, # (4) Exhibit D - Defendant's Claim Terms for Construction, # (5) Exhibit E - Defendant's Preliminary Constructions, # (6) Exhibit F - Plaintiff's Preliminary Infringement Contentions) (Evans, E.)
Sep 13, 2021	67	Motion to Strike (Main Document) (3) Docket Text: MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter)
Sep 13, 2021	67	Motion to Strike (Text of Proposed Order) (2) Docket Text: MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter)
Sep 13, 2021	68	Memorandum in Support (Main Document) (14) Docket Text: Memorandum in Support regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A) (Siddoway, Peter)
Sep 13, 2021	68	Memorandum in Support (Exhibit A) (12) Docket Text: Memorandum in Support regarding [67] MOTION to Strike Portions of Aquestive's Infringement Contentions filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A) (Siddoway, Peter)
Aug 19, 2021	65	Redacted Document (18) Docket Text: REDACTION to [47] PROPOSED SEALED Response, by Aquestive Therapeutics, Inc. (Evans, E.)
Aug 19, 2021	66	Redacted Document (15) Docket Text: REDACTION to [49] PROPOSED SEALED Exhibit, 1 to Declaration of Anna Targowska by Aquestive Therapeutics, Inc. (Evans, E.)
Aug 10, 2021	64	Order on Motion to Dismiss (1) Docket Text: ORDER denying [45] Motion to Dismiss. Signed by District Judge James C. Dever III on 8/10/2021. (Sellers, N.)
Aug 9, 2021	62	Order on Motion to Seal (3) Docket Text: ORDER granting [50] Motion to Seal. Signed by District Judge James C. Dever III on 8/9/2021. (Sellers, N.)
Aug 9, 2021	63	Order Appointing Mediator (1) Docket Text: ORDER Appointing Mediator Douglas W. Kenyon appointed. Signed by Peter A. Moore, Jr., Clerk of Court on 8/9/2021. (Horton, B.)
Jul 28, 2021	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [59] Consent MOTION Entry of Stipulated Order Governing Electronic Discovery. (Sellers, N.)
Jul 28, 2021	60	Order (9) Docket Text: STIPULATED ORDER GOVERNING ELECTRONIC DISCOVERY - Signed by District Judge James C. Dever III on 7/28/2021. (Sellers, N.)
Jul 28, 2021	61	Notice - other (2) Docket Text: Notice filed by Aquestive Therapeutics, Inc. Regarding Local ADR Rule 101.1c(a). (Evans, E.)
Jul 27, 2021	59	Motion for Miscellaneous Relief (Main Document) (2) Docket Text: Consent MOTION Entry of Stipulated Order Governing Electronic Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit 1 - Proposed Stiplated Order) (Evans, E.)
Jul 27, 2021	59	Motion for Miscellaneous Relief (Exhibit 1 - Proposed Stiplated Order) (10) Docket Text: Consent MOTION Entry of Stipulated Order Governing Electronic Discovery filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit 1 - Proposed Stiplated Order) (Evans, E.)
Jul 7, 2021	N/A	Notice to Counsel - Selection of Mediator (0) Docket Text: NOTICE TO COUNSEL - Pursuant to Local ADR Rule 101.1c(a), counsel is reminded that the parties must file a written statement identifying an agreed upon mediator within twenty one (21) days of the entry of the Scheduling Order. If a statement is not timely filed, the Clerk of Court will appoint a mediator from the list of court certified mediators. Selection of Mediator must be electronically filed on or before 7/28/2021. (Sellers, N.)
Jul 7, 2021	58	Scheduling Order (Main Document) (2) Docket Text: SCHEDULING ORDER: Except as modified, the Discovery Plan is APPROVED AND ORDERED with the deadlines in Exhibit A [D.E. 54-1] of the Joint Rule 26(f) Report and Discovery Plan. The court will set the case for trial by separate order. Counsel should read the order in its entirety for critical deadlines and information. Signed by District Judge James C. Dever III on 7/7/2021. (Sellers, N.) (Additional attachment(s) added on 7/7/2021: # (1) Consent to Magistrate Judge Jurisdiction Form) (Sellers, N.).
Jul 7, 2021	58	Scheduling Order (Consent to Magistrate Judge Jurisdiction Form) (1) Docket Text: SCHEDULING ORDER: Except as modified, the Discovery Plan is APPROVED AND ORDERED with the deadlines in Exhibit A [D.E. 54-1] of the Joint Rule 26(f) Report and Discovery Plan. The court will set the case for trial by separate order. Counsel should read the order in its entirety for critical deadlines and information. Signed by District Judge James C. Dever III on 7/7/2021. (Sellers, N.) (Additional attachment(s) added on 7/7/2021: # (1) Consent to Magistrate Judge Jurisdiction Form) (Sellers, N.).
Jul 2, 2021	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [56] Consent MOTION for Protective Order. (Sellers, N.)
Jul 2, 2021	56	Motion for Protective Order (Main Document) (2) Docket Text: Consent MOTION for Protective Order filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit 1 - Proposed Protective Order) (Evans, E.)
Jul 2, 2021	56	Motion for Protective Order (Exhibit 1 - Proposed Protective Order) (26) Docket Text: Consent MOTION for Protective Order filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit 1 - Proposed Protective Order) (Evans, E.)
Jul 2, 2021	57	Protective Order (25) Docket Text: PROTECTIVE ORDER regarding the Disclosure and Use of Discovery Materials - Signed by District Judge James C. Dever III on 7/2/2021. (Sellers, N.)
Jul 1, 2021	55	Notice of Special Appearance (2) Docket Text: Notice of Special Appearance for non-district by Benjamin R. Holt on behalf of Aquestive Therapeutics, Inc.. (Holt, Benjamin)
Jun 1, 2021	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [50] MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, [45] MOTION to Dismiss. (Sellers, N.)
May 25, 2021	54	Rule 26(f) Report (joint) (Main Document) (12) Docket Text: Rule 26(f) Report (joint) filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Schedule) (Evans, E.)
May 25, 2021	54	Rule 26(f) Report (joint) (Exhibit A - Proposed Schedule) (3) Docket Text: Rule 26(f) Report (joint) filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Proposed Schedule) (Evans, E.)
May 20, 2021	N/A	Motion Referred to Clerk (0) Docket Text: Motion Referred to Peter A. Moore, Jr., Clerk of Court regarding [53] Joint MOTION for Extension of Time to Submit Rule 26(f) Discovery Plan. (Sellers, N.)
May 20, 2021	N/A	Order on Motion for Extension of Time (0) Docket Text: TEXT ORDER granting the parties' Joint Motion for Extension of Time to Submit Rule 26(f) Discovery Plan [53]. For good cause shown, it is ordered that the parties have up to and including May 25, 2021, within which to file a Rule 26(f) Discovery Plan. Signed by Peter A. Moore, Jr., Clerk of Court on 5/20/2021. (Hockaday, A.)
May 19, 2021	53	Motion for Extension of Time (Main Document) (4) Docket Text: Joint MOTION for Extension of Time to Submit Rule 26(f) Discovery Plan filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
May 19, 2021	53	Motion for Extension of Time (Text of Proposed Order) (1) Docket Text: Joint MOTION for Extension of Time to Submit Rule 26(f) Discovery Plan filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
May 11, 2021	52	Reply to Response to Motion (Main Document) (17) Docket Text: REPLY to Response to Motion regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit H - 2017 Agreement Public) (Siddoway, Peter)
May 11, 2021	52	Reply to Response to Motion (Exhibit H - 2017 Agreement Public) (7) Docket Text: REPLY to Response to Motion regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit H - 2017 Agreement Public) (Siddoway, Peter)
Apr 27, 2021	48	Declaration (2) Docket Text: Declaration regarding [47] PROPOSED SEALED Response, In Opposition to Defendant's Motion to Dismiss by Aquestive Therapeutics, Inc. (Evans, E.)
Apr 27, 2021	50	Motion to Seal (Main Document) (3) Docket Text: MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Apr 27, 2021	50	Motion to Seal (Text of Proposed Order) (3) Docket Text: MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Apr 27, 2021	51	Memorandum in Support (Main Document) (6) Docket Text: Memorandum in Support regarding [50] MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, 1 to Declaration of Anna Targowska filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Redacted Opposition to Motion to Dismiss, # (2) Exhibit B - Redacted Exhibit 1 to Declaration) (Evans, E.)
Apr 27, 2021	51	Memorandum in Support (Exhibit A - Redacted Opposition to Motion to Dismiss) (18) Docket Text: Memorandum in Support regarding [50] MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, 1 to Declaration of Anna Targowska filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Redacted Opposition to Motion to Dismiss, # (2) Exhibit B - Redacted Exhibit 1 to Declaration) (Evans, E.)
Apr 27, 2021	51	Memorandum in Support (Exhibit B - Redacted Exhibit 1 to Declaration) (16) Docket Text: Memorandum in Support regarding [50] MOTION to Seal [47] PROPOSED SEALED Response, [49] PROPOSED SEALED Exhibit, 1 to Declaration of Anna Targowska filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Redacted Opposition to Motion to Dismiss, # (2) Exhibit B - Redacted Exhibit 1 to Declaration) (Evans, E.)
Apr 6, 2021	43	Response (23) Docket Text: ANSWER regarding [31] Answer to Complaint, Counterclaim by Aquestive Therapeutics, Inc. (Evans, E.) Modified on 4/6/2021 - clarified docket text. (Sellers, N.)
Apr 6, 2021	44	Order for Discovery Plan (1) Docket Text: ORDER FOR DISCOVERY PLAN sent to all parties. Signed by Peter A. Moore, Jr., Clerk of Court on 4/6/2021. (Sellers, N.)
Apr 6, 2021	45	Motion to Dismiss (Main Document) (3) Docket Text: MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter)
Apr 6, 2021	45	Motion to Dismiss (Text of Proposed Order) (1) Docket Text: MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Main Document) (15) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit A - Aquestive Stipulation) (4) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit B - Complaint) (10) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit C - Memorandum in Opposition) (24) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit D - Patent Owner's Notice) (7) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit E - Memorandum In Support) (30) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit F - Memorandum in Opposition) (30) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Apr 6, 2021	46	Memorandum in Support (Exhibit G - FDA News Release) (5) Docket Text: Memorandum in Support regarding [45] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit A - Aquestive Stipulation, # (2) Exhibit B - Complaint, # (3) Exhibit C - Memorandum in Opposition, # (4) Exhibit D - Patent Owner's Notice, # (5) Exhibit E - Memorandum In Support, # (6) Exhibit F - Memorandum in Opposition, # (7) Exhibit G - FDA News Release) (Siddoway, Peter)
Mar 25, 2021	N/A	Motion Referred to Clerk (0) Docket Text: Motion Referred to Peter A. Moore, Jr., Clerk of Court regarding [42] Consent MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint,, Counterclaim. (Sellers, N.)
Mar 25, 2021	N/A	Order on Motion for Extension of Time to Answer (0) Docket Text: TEXT ORDER granting Plaintiff's Consent Motion for Extension of Time [42]. For good cause shown, it is ordered that Plaintiff has up to and including April 6, 2021, within which to answer or otherwise respond to Defendant's Amended Counterclaims [31]. Signed by Peter A. Moore, Jr., Clerk of Court on 3/25/2021. (Hockaday, A.)
Mar 24, 2021	42	Motion for Extension of Time to File Answer (Main Document) (2) Docket Text: Consent MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint,, Counterclaim, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Mar 24, 2021	42	Motion for Extension of Time to File Answer (Text of Proposed Order) (1) Docket Text: Consent MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint,, Counterclaim, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Mar 16, 2021	41	Order on Motion to Dismiss (20) Docket Text: ORDER dismissing as moot [29] Motion to Dismiss, Motion to Strike; granting in part and denying in part [35] Motion to Dismiss; denying [35] Motion to Strike. Signed by District Judge James C. Dever III on 3/16/2021. (Sellers, N.)
Aug 12, 2020	40	Notice of Special Appearance (1) Docket Text: Notice of Special Appearance for non-district by Anna M. Targowska on behalf of Aquestive Therapeutics, Inc.. (Targowska, Anna)
Aug 5, 2020	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever, III regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint, Counterclaim, Fourth and Sixth Affirmative Defenses, [29] MOTION to Dismiss, MOTION to Strike [27] Answer to Complaint, Counterclaim. (Stouch, L.)
Jul 30, 2020	39	Reply to Response to Motion (12) Docket Text: REPLY to Response to Motion regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Jul 16, 2020	38	Memorandum in Opposition (Main Document) (26) Docket Text: Memorandum in Opposition regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Opinion in 2017-1265, # (2) Exhibit 2 - Opinion in 2019-1643, # (3) Exhibit 3 - Petition for Writ of Certiorari) (Siddoway, Peter)
Jul 16, 2020	38	Memorandum in Opposition (Exhibit 1 - Opinion in 2017-1265) (10) Docket Text: Memorandum in Opposition regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Opinion in 2017-1265, # (2) Exhibit 2 - Opinion in 2019-1643, # (3) Exhibit 3 - Petition for Writ of Certiorari) (Siddoway, Peter)
Jul 16, 2020	38	Memorandum in Opposition (Exhibit 2 - Opinion in 2019-1643) (16) Docket Text: Memorandum in Opposition regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Opinion in 2017-1265, # (2) Exhibit 2 - Opinion in 2019-1643, # (3) Exhibit 3 - Petition for Writ of Certiorari) (Siddoway, Peter)
Jul 16, 2020	38	Memorandum in Opposition (Exhibit 3 - Petition for Writ of Certiorari) (30) Docket Text: Memorandum in Opposition regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Opinion in 2017-1265, # (2) Exhibit 2 - Opinion in 2019-1643, # (3) Exhibit 3 - Petition for Writ of Certiorari) (Siddoway, Peter)
Jun 26, 2020	37	Notice - other (Main Document) (19) Docket Text: Notice filed by Aquestive Therapeutics, Inc. regarding [36] Memorandum in Support, Exhibit C - Monosol 01/26/16 Opposition to Motion to Exclude. (Attachments: # (1) Exhibit D - PTAB 03/24/16 Decision) (Evans, E.)
Jun 26, 2020	37	Notice - other (Exhibit D - PTAB 03/24/16 Decision) (30) Docket Text: Notice filed by Aquestive Therapeutics, Inc. regarding [36] Memorandum in Support, Exhibit C - Monosol 01/26/16 Opposition to Motion to Exclude. (Attachments: # (1) Exhibit D - PTAB 03/24/16 Decision) (Evans, E.)
Jun 25, 2020	35	Motion to Dismiss (3) Docket Text: MOTION to Dismiss Amended Third Counterclaim, MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Jun 25, 2020	36	Memorandum in Support (Main Document) (23) Docket Text: Memorandum in Support regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BioDelivery Sciences 11/23/15 Reply, # (2) Exhibit B - BioDelivery Sciences 01/11/16 Motion to Exclude) (Evans, E.)
Jun 25, 2020	36	Memorandum in Support (Exhibit A - BioDelivery Sciences 11/23/15 Reply) (29) Docket Text: Memorandum in Support regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BioDelivery Sciences 11/23/15 Reply, # (2) Exhibit B - BioDelivery Sciences 01/11/16 Motion to Exclude) (Evans, E.)
Jun 25, 2020	36	Memorandum in Support (Exhibit B - BioDelivery Sciences 01/11/16 Motion to Exclude) (19) Docket Text: Memorandum in Support regarding [35] MOTION to Dismiss Amended Third Counterclaim MOTION to Strike [31] Answer to Complaint,, Counterclaim, Fourth and Sixth Affirmative Defenses filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BioDelivery Sciences 11/23/15 Reply, # (2) Exhibit B - BioDelivery Sciences 01/11/16 Motion to Exclude) (Evans, E.)
Jun 11, 2020	34	Reply to Response to Motion (3) Docket Text: REPLY to Response to Motion regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Jun 4, 2020	N/A	Motion Referred to Clerk (0) Docket Text: Motion Referred to Peter A. Moore, Jr., Clerk of Court regarding [33] MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint, Counterclaim. (Sellers, N.)
Jun 4, 2020	N/A	Order on Motion for Extension of Time to Answer (0) Docket Text: TEXT ORDER granting Plaintiff's Consent Motion for Extension of Time [33]. For good cause shown, it is ordered that Plaintiff has up to and including June 25, 2020, within which to answer or otherwise respond to the Amended Counterclaim [31]. Signed by Peter A. Moore, Jr., Clerk of Court on 6/4/2020. (Hockaday, A.)
Jun 4, 2020	33	Motion for Extension of Time to File Answer (Main Document) (2) Docket Text: MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint,, Counterclaim, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
Jun 4, 2020	33	Motion for Extension of Time to File Answer (Text of Proposed Order) (1) Docket Text: MOTION for Extension of Time to File Answer regarding [31] Answer to Complaint,, Counterclaim, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Text of Proposed Order) (Evans, E.)
May 28, 2020	31	Answer to Complaint (Main Document) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 1) (10) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 2) (6) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 3) (11) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 4) (3) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 5) (6) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 6) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 7) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 8) (8) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 9) (15) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 10) (12) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 11) (11) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 12) (11) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 13) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	31	Answer to Complaint (Exhibit 14) (6) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , Amended COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12, # (13) Exhibit 13, # (14) Exhibit 14) (Siddoway, Peter)
May 28, 2020	32	Memorandum in Opposition (7) Docket Text: Memorandum in Opposition regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by BioDelivery Sciences International, Inc.. (Siddoway, Peter)
May 7, 2020	29	Motion to Dismiss (3) Docket Text: MOTION to Dismiss , MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Evans, E.)
May 7, 2020	30	Memorandum in Support (Main Document) (27) Docket Text: Memorandum in Support regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BDSI Reply, # (2) Exhibit B - BDSI Motion to Exclude, # (3) Exhibit C - Acquestive Opposition to Motion to Exclude, # (4) Exhibit D - USPTO Decision) (Evans, E.)
May 7, 2020	30	Memorandum in Support (Exhibit A - BDSI Reply) (29) Docket Text: Memorandum in Support regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BDSI Reply, # (2) Exhibit B - BDSI Motion to Exclude, # (3) Exhibit C - Acquestive Opposition to Motion to Exclude, # (4) Exhibit D - USPTO Decision) (Evans, E.)
May 7, 2020	30	Memorandum in Support (Exhibit B - BDSI Motion to Exclude) (19) Docket Text: Memorandum in Support regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BDSI Reply, # (2) Exhibit B - BDSI Motion to Exclude, # (3) Exhibit C - Acquestive Opposition to Motion to Exclude, # (4) Exhibit D - USPTO Decision) (Evans, E.)
May 7, 2020	30	Memorandum in Support (Exhibit C - Acquestive Opposition to Motion to Exclude) (19) Docket Text: Memorandum in Support regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BDSI Reply, # (2) Exhibit B - BDSI Motion to Exclude, # (3) Exhibit C - Acquestive Opposition to Motion to Exclude, # (4) Exhibit D - USPTO Decision) (Evans, E.)
May 7, 2020	30	Memorandum in Support (Exhibit D - USPTO Decision) (30) Docket Text: Memorandum in Support regarding [29] MOTION to Dismiss MOTION to Strike [27] Answer to Complaint,,, Counterclaim,, filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - BDSI Reply, # (2) Exhibit B - BDSI Motion to Exclude, # (3) Exhibit C - Acquestive Opposition to Motion to Exclude, # (4) Exhibit D - USPTO Decision) (Evans, E.)
Apr 16, 2020	27	Answer to Complaint (Main Document) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 1 - Patent Owner Response) (6) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 2 - Myers Decl) (6) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 3 - Myers Dep Transcript) (8) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 4 - Office Action Response) (5) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 5 - Request for Reexam) (30) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 6 - Lin Decl) (7) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 7 - Langer Dep Transcript) (15) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 8 - Wyse Decl) (12) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 9 - Wyse Dep Transcript) (9) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	27	Answer to Complaint (Exhibit 10 - Peppas Decl) (11) Docket Text: ANSWER to [1] Complaint,, with Jury Demand , COUNTERCLAIM against Aquestive Therapeutics, Inc. by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1 - Patent Owner Response, # (2) Exhibit 2 - Myers Decl, # (3) Exhibit 3 - Myers Dep Transcript, # (4) Exhibit 4 - Office Action Response, # (5) Exhibit 5 - Request for Reexam, # (6) Exhibit 6 - Lin Decl, # (7) Exhibit 7 - Langer Dep Transcript, # (8) Exhibit 8 - Wyse Decl, # (9) Exhibit 9 - Wyse Dep Transcript, # (10) Exhibit 10 - Peppas Decl) (Borchers, Lynne)
Apr 16, 2020	28	Financial Affidavit (2) Docket Text: FINANCIAL Disclosure Statement by BioDelivery Sciences International, Inc. (Borchers, Lynne) Modified on 4/17/2020 - changed docket text to reflect document filed. (Sellers, N.)
Apr 1, 2020	26	Order on Motion to Stay (1) Docket Text: ORDER denying [17] Motion to Stay; denying [20] Motion to Dismiss. Signed by District Judge James C. Dever III on 4/1/2020. (Sellers, N.)
Feb 25, 2020	N/A	Motion Submitted (0) Docket Text: Motion Submitted to District Judge James C. Dever III regarding [20] MOTION to Dismiss, [17] MOTION to Stay. (Sellers, N.)
Feb 18, 2020	25	Reply to Response to Motion (Main Document) (15) Docket Text: REPLY to Response to Motion regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 13 Langer Testimony Excerpts) (Borchers, Lynne)
Feb 18, 2020	25	Reply to Response to Motion (Exhibit 13 Langer Testimony Excerpts) (15) Docket Text: REPLY to Response to Motion regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 13 Langer Testimony Excerpts) (Borchers, Lynne)
Feb 3, 2020	24	Response in Opposition to Motion (27) Docket Text: RESPONSE in Opposition regarding [20] MOTION to Dismiss filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Jan 17, 2020	23	Response (3) Docket Text: RESPONSE regarding [22] Notice - other filed by BioDelivery Sciences International, Inc.. (Borchers, Lynne)
Jan 16, 2020	N/A	Notice - other (0) Docket Text: Notice - The hearing scheduled for 1/23/2020 before Chief US District Judge Terrence W. Boyle is cancelled. (Stouch, L.)
Jan 16, 2020	N/A	Order Reassigning Case (0) Docket Text: TEXT ORDER REASSIGNING CASE. At the direction of the Court, this case is reassigned to United States District Judge James C. Dever III for all further proceedings. Chief United States District Judge Terrence W. Boyle is no longer assigned to the case. All future filings shall reflect the revised case number of 5:19-CV-505-D. Signed by Peter A. Moore, Jr., Clerk of Court on 1/16/2020. (Hockaday, A.)
Jan 15, 2020	N/A	Set/Reset Motion and M&R Hearings (0) Docket Text: ***Set Hearing as to [17] MOTION to Stay. Motion Hearing set for 1/23/2020 at 11:00 AM in Raleigh - 7th Floor - Courtroom 2 before Chief Judge Terrence W. Boyle. (Stouch, L.)
Jan 14, 2020	22	Notice - other (Main Document) (3) Docket Text: Notice filed by Aquestive Therapeutics, Inc. of Decision of Federal Circuit. (Attachments: # (1) Exhibit A - Federal Circuit Order) (Evans, E.)
Jan 14, 2020	22	Notice - other (Exhibit A - Federal Circuit Order) (11) Docket Text: Notice filed by Aquestive Therapeutics, Inc. of Decision of Federal Circuit. (Attachments: # (1) Exhibit A - Federal Circuit Order) (Evans, E.)
Jan 13, 2020	20	Motion to Dismiss (Main Document) (3) Docket Text: MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Borchers, Lynne)
Jan 13, 2020	20	Motion to Dismiss (Text of Proposed Order) (1) Docket Text: MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Main Document) (30) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 1) (10) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 2) (2) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 3) (7) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 4) (13) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 5) (8) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 6) (13) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 7) (30) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 8) (30) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 9) (7) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 10) (30) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 11) (21) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 13, 2020	21	Memorandum in Support (Exhibit 12) (5) Docket Text: Memorandum in Support regarding [20] MOTION to Dismiss filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5, # (6) Exhibit 6, # (7) Exhibit 7, # (8) Exhibit 8, # (9) Exhibit 9, # (10) Exhibit 10, # (11) Exhibit 11, # (12) Exhibit 12) (Borchers, Lynne)
Jan 10, 2020	N/A	Motion Submitted (0) Docket Text: Motion Submitted to Chief Judge Terrence W. Boyle regarding [17] MOTION to Stay. (Stouch, L.)
Dec 18, 2019	19	Response in Opposition to Motion (Main Document) (22) Docket Text: RESPONSE in Opposition regarding [17] MOTION to Stay filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Fatpipe, Inc. v. Talari Networks, Inc. Order) (Evans, E.)
Dec 18, 2019	19	Response in Opposition to Motion (Exhibit A - Fatpipe, Inc. v. Talari Networks, Inc. Order) (4) Docket Text: RESPONSE in Opposition regarding [17] MOTION to Stay filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - Fatpipe, Inc. v. Talari Networks, Inc. Order) (Evans, E.)
Dec 10, 2019	N/A	Case Selected for Mediation (0) Docket Text: Case Selected for Mediation - A printable list of certified mediators for the Eastern District of North Carolina is available on the court's Website, http://www.nced.uscourts.gov/attorney/mediators.aspx. Please serve this list on all parties. (Stouch, L.)
Nov 27, 2019	14	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Wyley S. Proctor on behalf of BioDelivery Sciences International, Inc.. (Proctor, Wyley)
Nov 27, 2019	15	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Kia L. Freeman on behalf of BioDelivery Sciences International, Inc.. (Freeman, Kia)
Nov 27, 2019	16	Notice of Special Appearance (3) Docket Text: Notice of Special Appearance for non-district by Thomas F. Foley on behalf of BioDelivery Sciences International, Inc.. (Foley, Thomas)
Nov 27, 2019	17	Motion to Stay (Main Document) (2) Docket Text: MOTION to Stay filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Borchers, Lynne)
Nov 27, 2019	17	Motion to Stay (Text of Proposed Order) (1) Docket Text: MOTION to Stay filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Text of Proposed Order) (Borchers, Lynne)
Nov 27, 2019	18	Memorandum in Support (Main Document) (21) Docket Text: Memorandum in Support regarding [17] MOTION to Stay filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1) (Borchers, Lynne)
Nov 27, 2019	18	Memorandum in Support (Exhibit 1) (2) Docket Text: Memorandum in Support regarding [17] MOTION to Stay filed by BioDelivery Sciences International, Inc.. (Attachments: # (1) Exhibit 1) (Borchers, Lynne)
Nov 26, 2019	12	Notice of Appearance (2) Docket Text: Notice of Appearance filed by Lynne A. Borchers on behalf of BioDelivery Sciences International, Inc.. (Borchers, Lynne)
Nov 26, 2019	13	Notice of Appearance (2) Docket Text: Notice of Appearance filed by Peter D. Siddoway on behalf of BioDelivery Sciences International, Inc.. (Siddoway, Peter)
Nov 20, 2019	11	Notice of Special Appearance (1) Docket Text: Notice of Special Appearance for non-district by John l. Abramic on behalf of Aquestive Therapeutics, Inc.. (Abramic, John)
Nov 15, 2019	10	Waiver of Service Executed (1) Docket Text: Waiver of Service Returned Executed filed by Aquestive Therapeutics, Inc.. (Evans, E.)
Nov 14, 2019	9	Notice - other (2) Docket Text: Notice filed by Aquestive Therapeutics, Inc. of Amended Civil Cover Sheet. (Evans, E.)
Nov 12, 2019	6	Notice of Special Appearance (1) Docket Text: Notice of Special Appearance for non-district by James F. Hibey on behalf of Aquestive Therapeutics, Inc.. (Hibey, James)
Nov 12, 2019	7	Document (1) Docket Text: PATENT REPORT: Copy of report and complaint forwarded to Mail Stop 8, Director of the U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450 via US Mail on November 12, 2019. (Rudd, D.)
Nov 12, 2019	8	Summons Issued (2) Docket Text: Summons Issued as to BioDelivery Sciences International, Inc. (NOTICE: Counsel shall print the attached summons and serve with other case opening documents in accordance with Fed.R.Civ.P. 4.). (Rudd, D.)
Nov 11, 2019	1	Complaint* (1)
Nov 11, 2019	1	Complaint (Main Document) (30) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit A - '167 Patent) (30) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit B - Sirgo Affidavit) (3) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit C - BDSI BEMA Webpage) (4) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit D - Prescribing Information) (30) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit E - '866 Patent) (20) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit F - '843 Patent) (22) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit G - '539 Patent) (17) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Exhibit H - Chemistry Reviews) (21) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Civil Cover Sheet) (2) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	1	Complaint (Proposed Summons) (2) Docket Text: COMPLAINT against BioDelivery Sciences International, Inc. ( Filing fee $ 400 receipt number 0417-5178725.), filed by Aquestive Therapeutics, Inc.. (Attachments: # (1) Exhibit A - '167 Patent, # (2) Exhibit B - Sirgo Affidavit, # (3) Exhibit C - BDSI BEMA Webpage, # (4) Exhibit D - Prescribing Information, # (5) Exhibit E - '866 Patent, # (6) Exhibit F - '843 Patent, # (7) Exhibit G - '539 Patent, # (8) Exhibit H - Chemistry Reviews, # (9) Civil Cover Sheet, # (10) Proposed Summons) (Evans, E.)
Nov 11, 2019	2	Notice of Appearance (1) Docket Text: Notice of Appearance filed by E. Bradley Evans on behalf of Aquestive Therapeutics, Inc.. (Evans, E.)
Nov 11, 2019	3	Financial Affidavit (2) Docket Text: Financial Disclosure Statement filed by Aquestive Therapeutics, Inc. (Evans, E.) Modified on 11/12/2019 to change docket entry text. (Stouch, L.).
Nov 11, 2019	4	Notice of Appearance (1) Docket Text: Notice of Appearance filed by Joseph A. Schouten on behalf of Aquestive Therapeutics, Inc.. (Schouten, Joseph)
Nov 11, 2019	5	Notice of Special Appearance (1) Docket Text: Notice of Special Appearance for non-district by Jamie Lucia on behalf of Aquestive Therapeutics, Inc.. (Lucia, Jamie)

Lawsuits

Aquestive Therapeutics, Inc. v. BioDelivery Sciences International, Inc. > Documents